Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Completed · Phase 4

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

Key facts

Study ID

NCT00061802

Run by

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

People needed

225

Starts

2003-06-01

Expected to finish

2004-02-01

Last updated by the study team

2012-02-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — San Diego, California, United States
• Study site — Hoffman Est, Illinois, United States
• Study site — Lake Charles, Louisiana, United States
• Study site — Jackson, Mississippi, United States
• Study site — Visakhapatnam, Missouri, United States
• Study site — The Bronx, New York, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Aurangabad, India
• Study site — New Delhi, India
• Study site — Orange, India
• Study site — San Diego, India
• Study site — Lucknow, Romania
• Study site — Richmond, Romania

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.